



**INSTRUCTION DIVISION
FIRST SEMESTER 2015-2016
Course Handout (Part II)**

Date: 18/07/2016

In-addition to Part – I (General Handout for all courses appended to the time table) this portion gives further specific details regarding the course

Course No : **PHA G 617**
Course Title : Advanced Drug Delivery Systems
Instructor-in-charge : Dr. DEEPAK CHITKARA
Instructor : Dr. Anupama Mittal, Dr. Aniruddha Roy, Mr. Saurabh Sharma

1. Course Description

A study of physicochemical, biopharmaceutical and physiological factors involved in the design of novel drug delivery systems like mucosal, particulate systems for systemic delivery of bioactive molecules. Special considerations for delivery of protein, peptide and other biological products. In vitro and in vivo evaluation of novel drug delivery systems.

2. Scope and objective of the course :

The prime objective of this course is to impart knowledge of design, development and evaluation of novel drug delivery systems (NDDS). The primary focus would be on integrating the biopharmaceutical, physiochemical and physiological properties for design and development of (NDDS) with due consideration of pharmacological action. Excipients used in design and development of NDDS would be covered exhaustively. Various techniques involved in in vitro and in vivo evaluation of NDDS would be dealt at length. Special impetus would be given to IVIVC.

3. Text Book:

- i. Tyle, P. Specialized Drug Delivery Systems- Manufacturing and Production Technology, Marcel Dekker, New York, 1990

4. Reference Book:

- i. Prescott, L.F., and Nimmo, W.S. Novel Drug Delivery, John Wiley & Sons, Chichester, 1989.
- ii. McNally, E. J. Protein Formulation and Delivery, Marcel Dekker, New York, 2000.
- iii. Frokjaer, S., and Hovgaard, L. Pharmaceutical Formulation Development of Peptides and Proteins, Taylor and Francis, London, 2000.

5. Course Plan:

Lect. No.	Learning Objectives	Topics to Covered	Ref. Chap/Sc # (Book)
1-2	Overview of NDDS, Opportunities and challenges	General Introduction	T.1 CH.1
3-4	Various aspects affecting design, development and	Physicochemical, Biopharmaceutical and Physiological factors important for	R.3 CH. 2 &7, class notes





	selection of NDDS	design of NDDS, 4D approach	
5-6	Techniques used for development of NDDS	Various Techniques involved in development of NDDS	R.3 CH. 2 &7, class notes
8-15	Design and Physical characterization of advanced drug delivery systems	Microparticles, Nanoparticles, Liposomes, Polymeric micelles, Polymer drug conjugates, Dendrimers	T.1 CH.5, Journal articles, class notes
16-18	Targeted Drug delivery	Various drug delivery systems for site specific targeting, design parameters for tumor targeted delivery of nanotherapeutics.	R.3 CH.9,25,&32
19-21	Oral delivery of nano-therapeutics	Basic design considerations, mechanism of uptake via oral route, different nano-carrier systems for oral delivery	Class notes, Journal articles
22-24	Pulmonary delivery of nano-therapeutics	Basic design considerations, mechanism of uptake via pulmonary route	Class notes, Journal articles
25-29	Drug delivery of proteins and peptides	Basic considerations in the design of Protein/Peptide based delivery systems	T.1 CH.6, R.1 CH.29, R.2 CH.5
30-32	Immunotherapy	Use of advanced drug delivery systems for immunotherapy	These are advanced topics and will be covered using journal articles. Federal guidelines keep on changing so latest guidelines would be covered.
33-34	NanoRNAi	Introduction to siRNA, miRNA. Gene therapy mediated via nano-carriers	
35-36	In vitro Characterization	Various methods and techniques for in-vitro drug release and other characterization of NDDS	
37-38	In vivo Characterization and Evaluation	Selection of appropriate animal models for evaluation of various NDDS	
39-40	Novel Delivery devices	Various devices for controlled and site specific drug delivery	

6. Evaluation Scheme:

Component	Duration	Weightage (%)	Date & Time	Remarks
Mid Term Test	90 min	20	6/10 8:00 - 9:30 AM	CB
Lab component/ Literature Survey, Seminars/ Research Summaries/Assignments		50		
Comprehensive Exam	180 min	30	8/12 AN	CB

7. **Attendance:** Regularity in attendance will be one of the criteria in deciding borderline cases at the time of final grading.
8. **Notices:** Pharmacy Notice Board.
9. **Chamber Consultation Hour:** To be announced in the class.
10. **Make-up Policy:** Make-ups are not given as a routine. It is solely dependent on the “genuineness” of the circumstances under which a student fails to appear in a scheduled evaluation component. Prior permission should be sought from the instructor-in-charge in advance.





BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE, Pilani
Pilani Campus

Instructor-in-charge



Please Consider Your Environmental Responsibilities
Do Not Print Unless Necessary